Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 398 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypertrophic Clear all

Conditions: Cardiomyopathy, Hypertrophic, Dilated Cardiomyopathy, Duchenne Muscular Dystrophy, Cardiac Sarcoidosis, Becker Muscular Dystrophy, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction
Interventions: Hyperpolarized 13C-Pyruvate; Diagnostic Test
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pain, Postoperative, Tonsillar Hypertrophy, Tonsillitis, Pediatric Sleep Apnea, Sleep-Disordered Breathing
Interventions: Methadone, Fentanyl/Hydromorphone; Drug
Lead sponsor: Duke University; Other
Eligibility: 3 Years to 17 Years
Enrollment: 440 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Adenoid Hypertrophy
Interventions: Dextromethorphan, Acetaminophen, Dexmedetomidine, Ketamine; Drug
Lead sponsor: Arlyne Thung; Other
Eligibility: 4 Years to 8 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Aortic Stenosis, LV Remodeling, Hypertrophy
Interventions: Tadalafil, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions: Pacritinib, Physician's Choice medications; Drug
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: 18 Years and older
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 42
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 29 more

Conditions: Ann Arbor Stage II Grade 1 Follicular Lymphoma, Ann Arbor Stage II Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Bulky Disease, Fatigue, Fever, Grade 3a Follicular Lymphoma, Night Sweats, Splenomegaly, Weight Loss
Interventions: Lenalidomide, Obinutuzumab; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostatic Hyperplasia, Prostatic Hypertrophy, Benign
Interventions: Doxazosin, Finasteride, Doxazosin placebo, Finasteride placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 50 Years and older · Male only
Enrollment: 3,407 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1995 – 2001
U.S. locations: 17
States / cities: La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 13 more

Conditions: Hypertension, Left Ventricular Hypertrophy, Left Ventricular Dysfunction, Left Atrial Dilatation, Left Ventricular Diastolic Dysfunction, Kidney Diseases, Kidney Injury, Kidney Dysfunction, Sodium Urine High, Blood Pressure Disorders, Uric Acid Retention, Angiotensin Hypertension, Autonomic Dysfunction, Autonomic Imbalance, Pediatric Kidney Disease, Pediatric Obesity, Proteinuria, Albuminuria
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 7 Years to 18 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Hypophosphatemia, X-linked Hypophosphatemia, Renin-angiotensin System, Left Ventricular Hypertrophy
Interventions: Ang II and Ang-(1-7), FGF23 and klotho; Diagnostic Test
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 2 Years to 24 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Scars, Hypertrophic
Interventions: Treatment of hypertrophic scars (Soliton's Rapid Acoustic Pulse (RAP) Device); Device
Lead sponsor: Soliton; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Diego, California

Conditions: Non-obstructive Hypertrophic Cardiomyopathy, Hypertrophic Cardiomyopathy
Interventions: myPACE+ algorithm; Other
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Nonmalignant Neoplasm, Prostate Cancer
Interventions: dutasteride; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Kidney Calculi, Urologic Diseases, Benign Prostatic Hypertrophy
Interventions: Tranexamic acid; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 89 Years · Male only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cardiomyopathy, Hypertrophic Obstructive, Left Ventricular Outflow Tract Obstruction
Interventions: MYK-461; Drug
Lead sponsor: MyoKardia, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 7
States / cities: Scottsdale, Arizona • New Haven, Connecticut • Boston, Massachusetts + 4 more

Conditions: Colorectal Cancer Liver Metastases
Interventions: Portal and Hepatic Vein Embolization; Procedure
Lead sponsor: Maastricht University; Other
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: New Haven, Connecticut • Chicago, Illinois • New York, New York

Conditions: HCC, Resection, Transplant, Metastatic Cancer, Adult Primary Liver Cancer
Interventions: Y90 radioembolization; Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Jacksonville, Florida • Chicago, Illinois

Conditions: Scar, Hypertrophic Scar
Interventions: Botulinum Toxin, Normal saline; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Hypertrophic Cardiomyopathy
Interventions: Pirfenidone; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Keloid, Alopecia Areata, Acne, Hypertrophic Scar, Epidermal Inclusion Cyst, Frontal Fibrosing Alopecia, Lichen Plano-Pilaris, Keratoacanthoma, Plaque Psoriasis, Lichen Simplex Chronicus, Prurigo Nodularis, Nummular Eczema, Granuloma Annulare, Morphea, Lichen Planus
Interventions: Corticosteroid with lidocaine, Corticosteroid with normal saline; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 12 Years and older
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Benign Prostatic Hypertrophy, Lower Urinary Tract Symptoms
Interventions: Embosphere microspheres; Device
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 50 Years and older · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Wrinkle, Acne Scars - Mixed Atrophic and Hypertrophic, Pigmented Lesions, Skin Laxity, Scars
Interventions: MIRIA; Device
Lead sponsor: AVAVA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Dix Hills, New York • New York, New York

Conditions: Hypertrophic Cardiomyopathy
Interventions: Pacemaker therapy; Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Gastric Cancer, Precancerous Condition
Interventions: Cetuximab; Biological
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 3
States / cities: Nashville, Tennessee

Conditions: Hypertrophy, Left Ventricular, Hypertension, Cardiomyopathies
Interventions: Intervention: Population Health Coordinator; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 30 Years to 75 Years
Enrollment: 648 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

UTSW HP [13-C] Pyruvate Injection in HCM

Optimization of Pediatric Tonsillectomy to IMprove AnaLgesia

A Pilot Study: a Non-opioid Technique for Postoperative Adenoidectomy Pain Relief in Pediatric Patients

Aortic Stenosis and PhosphodiEsterase Type 5 iNhibition (ASPEN): A Pilot Study

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma

Medical Therapy of Prostatic Symptoms

Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)

FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP)

Treatment of Fibrotic Scars With Rapid Acoustic Pulse (RAP) Device

Effect of Personalized Accelerated Pacing in Symptomatic Patients With Non-Obstructive Hypertrophic Cardiomyopathy

MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer

Tranexamic Acid to Improve Same-day Discharge Rates After Holmium Laser Enucleation of the Prostate (HoLEP)

A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

DRAGON 1- Training, Accreditation, Implementation and Safety Evaluation of Combined PVE/HVE

Optimizing Y90 Therapy for Radiation Lobectomy

Randomized Controlled Trial Examining the Efficacy of Botulinum Toxin in Biopsy Scar Minimization

Pirfenidone to Treat Hypertrophic Cardiomyopathy

Pain Outcomes Following Intralesional Corticosteroid Injections

Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH)

AV-23-001 AVAVA MIRIA Pilot Study

Studying the Effectiveness of Pacemaker Therapy in Children Who Have Thickened Heart Muscle

Cetuximab in Treating Patients With Ménétrier Disease at High Risk of Developing Stomach Cancer

Effect of a Targeted Notification and Clinical Support Pathway on Individuals With Left Ventricular Hypertrophy